Analyzing Cost of Revenue: Zoetis Inc. and Grifols, S.A.

Zoetis vs. Grifols: A Decade of Cost Dynamics

__timestamp	Grifols, S.A.	Zoetis Inc.
Wednesday, January 1, 2014	1656170000	1717000000
Thursday, January 1, 2015	2003565000	1738000000
Friday, January 1, 2016	2137539000	1666000000
Sunday, January 1, 2017	2166062000	1775000000
Monday, January 1, 2018	2437164000	1911000000
Tuesday, January 1, 2019	2757459000	1992000000
Wednesday, January 1, 2020	3084873000	2057000000
Friday, January 1, 2021	2970522000	2303000000
Saturday, January 1, 2022	3832437000	2454000000
Sunday, January 1, 2023	4269276000	2710000000
Monday, January 1, 2024		2719000000

Cracking the code

Analyzing Cost of Revenue: Zoetis Inc. vs. Grifols, S.A.

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, Zoetis Inc. and Grifols, S.A. have shown distinct trends in their cost of revenue. Grifols, S.A. experienced a significant increase of approximately 158% over this period, peaking in 2023. Meanwhile, Zoetis Inc. saw a steady rise of about 58%, reflecting its strategic cost management. Notably, Grifols' cost of revenue surpassed Zoetis' by nearly 58% in 2023, highlighting its expansive operations. This data underscores the importance of cost efficiency in maintaining competitive advantage. As the pharmaceutical landscape continues to shift, these insights offer a glimpse into the financial strategies of two industry leaders.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025